Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc. on February 6, 2026, reporting an event that occurred on February 4, 2026. The filing pertains to corporate governance changes, specifically the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Gregg C. E. Johnson as an independent director of the Board, effective February 4, 2026. Mr. Johnson will also serve on the Compensation Committee.
Compensation and Background
- Compensation: Mr. Johnson will receive an annual non-employee director cash fee of $48,000 plus $5,000 per committee membership. He is also eligible for stock option compensation under the Company's 2024 Equity Incentive Plan.
- Background: Mr. Johnson (age 61) previously served as the Company's Secretary (2016-2020) and Director (2016-2018). His recent experience includes serving as CEO of Serenus Global Inc. (2021-2024) and Upeva, Inc. (2018-2021), and as a director of Omnia Resource Development Corporation (since 2022).
Outlook, Risks, and Contingencies
The filing does not contain guidance, outlook, management commentary on financial performance, or specific risk factors beyond standard disclosures regarding the absence of family relationships or material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Confirmation of Gregg C. E. Johnson's effective start date as Director (February 4, 2026).
- Verification of the specific terms of the 2024 Equity Incentive Plan regarding stock options for new directors.
- Review of the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.
- Assessment of Mr. Johnson's prior tenure with the Company and potential conflicts of interest, though the filing states none exist.